	US 11,850,281 B2
	Rev-dependent lentiviral vaccine particles for reducing viral rebound and viral reservoirs in vivo
Yuntao Wu, Manassas, VA (US)
Assigned to George Mason Research Foundation, Inc., Fairfax, VA (US)
Appl. No. 16/758,577
Filed by Yuntao Wu, Manassas, VA (US)
PCT Filed Oct. 23, 2018, PCT No. PCT/US2018/057065 § 371(c)(1), (2) Date Apr. 23, 2020, PCT Pub. No. WO2019/083976, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/575,629, filed on Oct. 23, 2017.
Prior Publication US 2020/0345833 A1, Nov. 5, 2020
Int. Cl. A61P 31/18 (2006.01); A61K 39/02 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/02 (2013.01) [A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/18 (2018.01); A61K 2039/5256 (2013.01); C12N 2710/16634 (2013.01); C12N 2710/16671 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15071 (2013.01)]

7 Claims

1. A method for killing of HIV+positive cells to a subject in need thereof, comprising:

(a) administering an antibody or anti-HIV/SIV drug to deplete CD8 T cells from the subject's body to ensure no rejection of a therapeutic vaccine by the body's killer T cells (CD8);

(b) injecting a HIV vaccine particle comprising a Rev-dependent vector system for selective killing of HIV-infected cells;

(c) ceasing anti-HIV therapy with combination antiretroviral therapy (cART) during vaccine particle injection for a period sufficient to allow the injected vaccine particles to amplify and replicate; and

(d) following vaccine particle amplification, reinitiating anti-HIV therapy with combination antiretroviral therapy (cART) to decrease viral load to a base line.